Cubicin Articles
Hospira challenges Cubist patents on Cubicin
10 February 2012
Vancomycin continues to dominate MRSA treatment with up to 76% of US specialists using the drug; Study
25 May 2011
Novartis to pay up to $485 million for Paratek’s IV antibiotic
12 October 2009
Cubist up on Novartis $1.6B buy rumors
9 April 2009
Analysts expect profit for Theravance in 2012
2 March 2009
Cubist told of Teva ANDA submission for Cubicin
16 February 2009
Cubist's sales jump 47% on Cubicin sales
9 February 2009
Cubist income up as Cubicin sales rise 45%
27 October 2008
Cubist to promote AstraZeneca's Merrem in USA
7 July 2008
SMC OKs Cubicin for MRSA indications
17 March 2008
Novartis' MRSA drug Cubicin launched in UK
24 September 2007
AstraZeneca pays Cubist $10.25M up front for Asian right to Cubicin
18 December 2006
Italian drug spending rises 9.2%
20 November 2006
Strong Ph III data on Cubist's Cubicin
28 August 2006
Telavancin disappoints, Cubist shares rise
28 August 2006
FDA OKs expanded label for Cubist's Cubicin
5 June 2006
Chiron's Cubicin launched in UK
3 April 2006
Chiron launches Cubicin in EU
30 January 2006
Cubist shares jump on Ph III Cubicin trial
4 July 2005
Cubist/Chiron's Cubicin filed in EU
13 December 2004
Cubist and Chiron to file for EU appro on Cubicin
14 June 2004
Cubist's Cubicin available in the USA
10 November 2003
Chiron licenses Cubist's Cubicin
13 October 2003
Cubist's antibiotic cleared by FDA
22 September 2003
Showing 1-31 of 31 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
